These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37939517)

  • 1. Head and neck cancer stem cell maintenance relies on mTOR signaling, specifically involving the mechanistic target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2).
    Almeida LO; Silva LC; Emerick C; Amorim Dos Santos J; Castilho RM; Squarize CH
    Arch Oral Biol; 2024 Jan; 157():105840. PubMed ID: 37939517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
    Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
    Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.
    Zhu N; Wang Q; Wu Z; Wang Y; Zeng MS; Yuan Y
    J Virol; 2022 Mar; 96(5):e0194121. PubMed ID: 35019715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
    Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
    Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency.
    Chen CJ; Sgritta M; Mays J; Zhou H; Lucero R; Park J; Wang IC; Park JH; Kaipparettu BA; Stoica L; Jafar-Nejad P; Rigo F; Chin J; Noebels JL; Costa-Mattioli M
    Nat Med; 2019 Nov; 25(11):1684-1690. PubMed ID: 31636454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication.
    Carter CC; Mast FD; Olivier JP; Bourgeois NM; Kaushansky A; Aitchison JD
    Front Cell Infect Microbiol; 2022; 12():979996. PubMed ID: 36171757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
    Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
    Matsubara S; Tsukasa K; Kuwahata T; Takao S
    Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic modeling of signal transduction by mTOR complexes in cancer.
    Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
    J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q; Song XM; Ji YY; Jiang H; Xu LG
    Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic hyperactivation of both mTORC1 and mTORC2 underlies the neural abnormalities of PTEN-deficient human neurons and cortical organoids.
    Dhaliwal NK; Weng OY; Dong X; Bhattacharya A; Ahmed M; Nishimura H; Choi WWY; Aggarwal A; Luikart BW; Shu Q; Li X; Wilson MD; Moffat J; Wang LY; Muffat J; Li Y
    Cell Rep; 2024 May; 43(5):114173. PubMed ID: 38700984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin and mTORC2 inhibition synergistically reduce contraction-stimulated muscle protein synthesis.
    Ogasawara R; Knudsen JR; Li J; Ato S; Jensen TE
    J Physiol; 2020 Dec; 598(23):5453-5466. PubMed ID: 32893874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOP14-mediated ribosome biogenesis is required for mTORC2 activation and predicts rapamycin sensitivity.
    Yan X; Kuang BH; Ma S; Wang R; Lin J; Zeng YX; Xie X; Feng L
    J Biol Chem; 2024 Mar; 300(3):105681. PubMed ID: 38272224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
    Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
    J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.